$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000106282222000035 Filed on August 03, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$39.00K	$35.00K	$37.00K
YoY Change	69.57%	-85.04%	37.04%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$39.00K	$35.00K
YoY Change	69.57%	-85.04%
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$12.58M	$10.69M	$8.491M
YoY Change	72.22%	34.65%	2.3%
% of Gross Profit	32248.72%	30531.43%
Research & Development	$10.56M	$13.36M	$14.93M
YoY Change	-32.68%	30.21%	18.38%
% of Gross Profit	27069.23%	38160.0%
Depreciation & Amortization	$108.0K	$107.0K	$109.0K
YoY Change	6.93%	35.44%	194.59%
% of Gross Profit	276.92%	305.71%
Operating Expenses	-$23.13M	-$24.04M	$23.42M
YoY Change	-200.65%	-232.15%	12.23%
Operating Profit	-$23.10M	-$24.01M	-$23.38M
YoY Change	0.58%	33.68%	12.19%
Interest Expense	$864.0K	$703.0K	$110.0K
YoY Change	405.26%	315.98%	-34.13%
% of Operating Profit
Other Income/Expense, Net	$572.0K	$123.0K	$14.00K
YoY Change	5100.0%	101.64%	-70.83%
Pretax Income	-$23.39M	-$24.59M	-$23.48M
YoY Change	1.15%	36.09%	11.79%
Income Tax
% Of Pretax Income
Net Earnings	-$23.39M	-$24.59M	-$23.48M
YoY Change	1.15%	36.09%	12.01%
Net Earnings / Revenue	-59966.67%	-70248.57%	-63448.65%
Basic Earnings Per Share	-$0.13	-$0.16	-$0.16
Diluted Earnings Per Share	-$133.7K	-$164.3K	-$157.4K
COMMON SHARES
Basic Shares Outstanding	183.6M shares	149.6M shares	149.2M shares
Diluted Shares Outstanding	174.9M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$136.2M	$61.97M	$86.50M
YoY Change	12.64%	-47.71%	-38.82%
Cash & Equivalents	$18.83M	$21.45M	$59.52M
Short-Term Investments	$117.4M	$40.52M	$26.98M
Other Short-Term Assets	$2.821M	$2.896M	$1.892M
YoY Change	-7.93%	-37.02%	-52.15%
Inventory
Prepaid Expenses
Receivables	$39.00K	$34.00K	$37.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$139.1M	$64.90M	$88.43M
YoY Change	12.14%	-47.35%	-39.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$932.0K	$1.035M	$1.142M
YoY Change	-28.91%	-13.82%	285.81%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.147M	$1.849M	$2.062M
YoY Change	189.24%	-30.75%	-31.38%
Total Long-Term Assets	$52.62M	$47.43M	$47.75M
YoY Change	8.89%	-2.04%	-0.2%
TOTAL ASSETS
Total Short-Term Assets	$139.1M	$64.90M	$88.43M
Total Long-Term Assets	$52.62M	$47.43M	$47.75M
Total Assets	$191.7M	$112.3M	$136.2M
YoY Change	11.23%	-34.57%	-29.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.427M	$7.347M	$9.321M
YoY Change	12.97%	-14.02%	89.22%
Accrued Expenses	$9.018M	$9.515M	$9.584M
YoY Change	-36.53%	-24.45%	-57.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.45M	$16.86M	$18.91M
YoY Change	-46.14%	-48.61%	-51.52%
LONG-TERM LIABILITIES
Long-Term Debt	$23.78M	$23.63M	$23.48M
YoY Change
Other Long-Term Liabilities	$5.438M	$1.002M	$1.098M
YoY Change	267.18%	-38.3%	-36.09%
Total Long-Term Liabilities	$29.22M	$24.63M	$24.58M
YoY Change	1873.13%	1416.81%	1330.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.45M	$16.86M	$18.91M
Total Long-Term Liabilities	$29.22M	$24.63M	$24.58M
Total Liabilities	$47.67M	$41.50M	$43.48M
YoY Change	33.42%	20.49%	6.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.559B	-$1.536B	-$1.511B
YoY Change	6.64%	6.73%	6.35%
Common Stock	$189.0K	$150.0K	$150.0K
YoY Change	26.0%	2.74%	3.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.061M	$2.061M	$2.061M
YoY Change	-72.59%	-72.59%	-72.59%
Treasury Stock Shares	488.0K shares	488.0K shares	488.0K shares
Shareholders Equity	$144.0M	$70.83M	$92.70M
YoY Change
Total Liabilities & Shareholders Equity	$191.7M	$112.3M	$136.2M
YoY Change	11.23%	-34.57%	-29.54%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$23.39M	-$24.59M	-$23.48M
YoY Change	1.15%	36.09%	12.01%
Depreciation, Depletion And Amortization	$108.0K	$107.0K	$109.0K
YoY Change	6.93%	35.44%	194.59%
Cash From Operating Activities	-$19.44M	-$24.42M	-$23.42M
YoY Change	13.35%	11.83%	-6.91%
INVESTING ACTIVITIES
Capital Expenditures	-$4.000K	$0.00	$76.00K
YoY Change	-98.12%	-100.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	-$77.19M	-$13.65M	-$4.332M
YoY Change	41179.14%	-190.39%	-75.53%
Cash From Investing Activities	-$77.20M	-$13.65M	-$4.408M
YoY Change	19199.0%	-196.7%	-75.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$864.0K
YoY Change			-106.05%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	94.02M	0.000	$23.28M
YoY Change	375.3%	-100.0%	63.14%
NET CHANGE
Cash From Operating Activities	-19.44M	-24.42M	-$23.42M
Cash From Investing Activities	-77.20M	-13.65M	-$4.408M
Cash From Financing Activities	94.02M	0.000	$23.28M
Net Change In Cash	-2.616M	-38.07M	-$4.545M
YoY Change	-217.26%	389.58%	-84.11%
FREE CASH FLOW
Cash From Operating Activities	-$19.44M	-$24.42M	-$23.42M
Capital Expenditures	-$4.000K	$0.00	$76.00K
Free Cash Flow	-$19.43M	-$24.42M	-$23.50M
YoY Change	14.75%	17.11%	-6.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30111
	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2445 Technology Forest Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	11th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
	dei	Local Phone Number LocalPhoneNumber	863-3000
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
	dei	City Area Code CityAreaCode	281
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	LXRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	183625743	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21450000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	40518000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	22678000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2896000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2164000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	64898000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	88921000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5070000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4853000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1035000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1176000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	44543000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	44543000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1849000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2269000	usd
CY2022Q2	us-gaap	Assets Assets	112325000	usd
CY2021Q4	us-gaap	Assets Assets	136909000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7347000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9152000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9515000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12972000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16862000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22124000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23631000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1002000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1190000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	41495000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	23314000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150114000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150082000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	150000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	150000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1608730000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1608749000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1535839000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1487776000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-150000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10000	usd
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	488000	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1165000	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2061000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7518000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	70830000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	113595000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112325000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136909000	usd
CY2022Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	35000	usd
CY2021Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	234000	usd
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	72000	usd
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	261000	usd
CY2022Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1098000	usd
CY2021Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1184000	usd
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2130000	usd
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2470000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13356000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10257000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28282000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22866000	usd
CY2022Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1734000	usd
CY2021Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1602000	usd
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	3474000	usd
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	3167000	usd
CY2022Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	10686000	usd
CY2021Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	7936000	usd
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	19177000	usd
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	16193000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	-24042000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	18193000	usd
	us-gaap	Operating Expenses OperatingExpenses	47459000	usd
	us-gaap	Operating Expenses OperatingExpenses	39059000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-24007000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17959000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-47387000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38798000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	703000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	169000	usd
	us-gaap	Interest Expense InterestExpense	813000	usd
	us-gaap	Interest Expense InterestExpense	336000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	123000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	61000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	137000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	109000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-24587000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-18067000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-48063000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-39025000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	149616000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144451000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	149384000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143917000	shares
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-113000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-140000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24700000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18077000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48203000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39024000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156371000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2851000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	548000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16399000	usd
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2675000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	152547000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2786000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	31000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	137233000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	113595000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2772000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	698000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	864000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-23476000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	92698000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2832000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-24587000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-113000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70830000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-48063000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-39025000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	216000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5604000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5637000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	179000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	29000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-236000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	732000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-451000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-420000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-261000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5447000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-14707000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47843000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47039000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	985000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	40171000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	24373000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	22191000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	21772000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18056000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3586000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16924000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	864000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2675000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24148000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23284000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14249000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42615000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-36376000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126263000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21450000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	89887000	usd
	us-gaap	Interest Paid Net InterestPaidNet	634000	usd
	us-gaap	Interest Paid Net InterestPaidNet	307000	usd
CY2022Q2	lxrx	Initial Recognition Of Right Of Use Asset InitialRecognitionOfRightOfUseAsset	0	usd
CY2021Q2	lxrx	Initial Recognition Of Right Of Use Asset InitialRecognitionOfRightOfUseAsset	1704000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	698	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	6321	usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
	us-gaap	Business Exit Costs1 BusinessExitCosts1	1500	usd
	us-gaap	Business Exit Costs1 BusinessExitCosts1	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2022Q2	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3920000	usd
CY2021Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3669000	usd
CY2022Q2	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	4329000	usd
CY2021Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	5711000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	789000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1089000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	477000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2503000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	9515000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	12972000	usd
CY2021Q1	lxrx	Lexicon Incremental Borrowing Rate LexiconIncrementalBorrowingRate	9
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	21450000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	40518000	usd
CY2022Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	61968000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	64065000	usd
CY2021Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	22678000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	86743000	usd
CY2022Q2	lxrx	Oxford Loan Facility OxfordLoanFacility	150000000	usd
CY2026Q1	lxrx	A2027 Oxford Principal Payments A2027OxfordPrincipalPayments	8700000	usd
CY2027Q1	lxrx	A2026 Oxford Principal Payments A2026OxfordPrincipalPayments	13000000	usd
CY2028Q1	lxrx	A2027 Oxford Principal Payments A2027OxfordPrincipalPayments	4800000	usd
CY2022Q2	lxrx	Term Loan A TermLoanA	25000000	usd
CY2022Q2	lxrx	Term Loan B TermLoanB	25000000	usd
CY2022Q2	lxrx	Term Loan C TermLoanC	50000000	usd
CY2022Q2	lxrx	Term Loan D TermLoanD	50000000	usd
CY2022Q2	lxrx	Term Loan Ab Warrant TermLoanABWarrant	0.0350
CY2022Q2	lxrx	Term Loan C Warrant TermLoanCWarrant	0.0175
CY2022Q2	lxrx	Term Loan D Warrant TermLoanDWarrant	0.00875
CY2022Q2	lxrx	Term Loan A Warrants Number TermLoanAWarrantsNumber	420673	shares
CY2022Q2	lxrx	Term Loan A Warrant Exercise Price TermLoanAWarrantExercisePrice	2.08
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
CY2022Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0790
CY2022Q2	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0801
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.0902
CY2022Q2	lxrx	Final Payment With No Extention FinalPaymentWithNoExtention	0.06	rate
CY2022Q2	lxrx	Final Payment With Extention FinalPaymentWithExtention	0.07	rate
CY2022Q2	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
CY2022Q2	lxrx	Term Loan A Net Cash Receipt TermLoanANetCashReceipt	24200000	usd
CY2022Q2	lxrx	Term Loan A Debt Issuance Costs TermLoanADebtIssuanceCosts	400000	usd
CY2022Q2	lxrx	Oxford Facility Fee OxfordFacilityFee	500000	usd
CY2022Q2	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
CY2022Q2	lxrx	Term Loan A Debt Discount TermLoanADebtDiscount	2900000	usd
	lxrx	Term Loan A Interest Expense TermLoanAInterestExpense	800000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	23600000	usd
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	usd
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2020Q3	lxrx	Convertible Debt Exchange Total Principal Amount ConvertibleDebtExchangeTotalPrincipalAmount	75800000	usd
CY2021Q4	lxrx	Convertible Debt Exchange Remaining Notes ConvertibleDebtExchangeRemainingNotes	11600000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000	usd
CY2022Q2	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	800000	usd
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1000000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	583000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	531000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	544000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	370000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2028000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	237000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1791000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	789000	usd
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1002000	usd
CY2021Q2	lxrx	Shares Sold In January2021 Atm Offering SharesSoldInJanuary2021ATMOffering	2000000	shares
CY2021Q2	lxrx	Share Price In January2021 Atm Offering SharePriceInJanuary2021ATMOffering	8.463	shares
CY2021Q2	lxrx	Proceeds From January2021 Atm Offering ProceedsFromJanuary2021ATMOffering	16400000	usd
CY2021Q4	lxrx	Shares Sold In September2021 Atm Offerring SharesSoldInSeptember2021ATMOfferring	4176953	shares
CY2021Q4	lxrx	Share Price In September2021 Atm Offerring SharePriceInSeptember2021ATMOfferring	4.732	usd
CY2021Q4	lxrx	Proceeds From September2021 Atm Offering ProceedsFromSeptember2021ATMOffering	19.1	usd
CY2022Q3	lxrx	Shares Sold In July2022 Offering SharesSoldInJuly2022Offering	34000000	shares
CY2022Q3	lxrx	Share Price In July2022 Offering SharePriceInJuly2022Offering	2.50	usd
CY2022Q3	lxrx	Proceeds From July2022 Offering ProceedsFromJuly2022Offering	82200000	usd

Files In Submission

Name	View Source	Status
0001062822-22-000035-index-headers.html	Edgar Link	pending
0001062822-22-000035-index.html	Edgar Link	pending
0001062822-22-000035.txt	Edgar Link	pending
0001062822-22-000035-xbrl.zip	Edgar Link	pending
exh31-fifthamendedandresta.htm	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20220630.htm	Edgar Link	pending
lxrx-20220630.xsd	Edgar Link	pending
lxrx-20220630_cal.xml	Edgar Link	unprocessable
lxrx-20220630_def.xml	Edgar Link	unprocessable
lxrx-20220630_htm.xml	Edgar Link	completed
lxrx-20220630_lab.xml	Edgar Link	unprocessable
lxrx-20220630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2022 Q3 Form 10-Q Financial Statement

#000106282222000035 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2022 Q3 Form 10-Q Financial Statement

#000106282222000035 Filed on August 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx